Literature DB >> 11122908

Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders.

D I Kaufer1.   

Abstract

Acetylcholine is a modulatory central nervous system (CNS) neurotransmitter involved in diverse brain processes. Historically, drugs that increase CNS cholinergic transmission have been investigated primarily for relieving cognitive symptoms in Alzheimer"s disease (AD). Emerging from these efforts are recent findings that several cholinesterase-inhibitor agents also have a beneficial effect on selected noncognitive symptoms in AD, such as apathy, psychosis, and purposeless motor behaviors. The broad psychotropic effects of cholinergic agents observed in AD and other degenerative conditions highlight potential symptom-based therapeutic indications for these drugs across a variety of neurologic disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11122908     DOI: 10.1007/s11920-999-0013-1

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  26 in total

1.  Use of donepezil for vascular dementia: preliminary clinical experience.

Authors:  M F Mendez; F L Younesi; K M Perryman
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1999       Impact factor: 2.198

2.  Cholinesterase inhibition in Parkinson's disease.

Authors:  M Hutchinson; E Fazzini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

Review 3.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

Review 4.  Cognitive functions of cortical acetylcholine: toward a unifying hypothesis.

Authors:  M Sarter; J P Bruno
Journal:  Brain Res Brain Res Rev       Date:  1997-02

Review 5.  The cholinergic hypothesis of Alzheimer's disease: a review of progress.

Authors:  P T Francis; A M Palmer; M Snape; G K Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

Review 6.  Pharmacologic challenges in Alzheimer disease and normal controls: cognitive modeling in humans.

Authors:  T Sunderland; S E Molchan; J T Little; M Bahro; K T Putnam; H Weingartner
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

Review 7.  Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease.

Authors:  M A Raskind; E R Peskind
Journal:  Alzheimer Dis Assoc Disord       Date:  1994       Impact factor: 2.703

8.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

9.  Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients.

Authors:  C Shea; C MacKnight; K Rockwood
Journal:  Int Psychogeriatr       Date:  1998-09       Impact factor: 3.878

10.  Physostigmine ameliorates the delusions of Alzheimer's disease.

Authors:  J L Cummings; D G Gorman; J Shapira
Journal:  Biol Psychiatry       Date:  1993-04-01       Impact factor: 13.382

View more
  1 in total

1.  An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.

Authors:  Ellen M Whyte; Eric J Lenze; Meryl Butters; Elizabeth Skidmore; Kris Koenig; Mary Amanda Dew; Louis Penrod; Benoit H Mulsant; Bruce G Pollock; Leonard Cabacungan; Charles F Reynolds; Michael C Munin
Journal:  Cerebrovasc Dis       Date:  2008-07-31       Impact factor: 2.762

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.